| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| atenolol | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 14/06/2025 |
| Measles virus~Mumps virus~live varicella vaccine~Rubella virus | Injection, powder for | 1000 CCID50~25119 CCID50~1995 PFU~1000 CCID50 | Anticipated | Available | Manufacturing | 13/06/2025 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| bupivacaine hydrochloride | Injection, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 13/06/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.82 mg/mL | Current | Unavailable | Manufacturing | 13/06/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| atazanavir sulfate | Capsule, hard | 341.69 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/06/2025 |
| midazolam | Injection, solution | 5 mg/mL | Resolved | Available | Manufacturing | 13/06/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| phenobarbital sodium | Injection, solution | 219 mg/mL | Current | Unavailable | Manufacturing | 13/06/2025 |
| oxazepam | Tablet, uncoated | 15 mg | Discontinued | Unavailable | Manufacturing | 13/06/2025 |
| metronidazole | Tablet, uncoated | 400 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Resolved | Available | Unexpected increase in consumer demand | 13/06/2025 |
| risedronate sodium hemipentahydrate | Tablet, film coated | 173.4 mg | Current | Limited Availability | Manufacturing | 13/06/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Anticipated | Available | Manufacturing | 13/06/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/06/2025 |
| sumatriptan succinate | Tablet, film coated | 139.98 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| candesartan cilexetil | Tablet, uncoated | 32 mg | Anticipated | Available | Manufacturing | 13/06/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Current | Unavailable | Unexpected increase in consumer demand | 13/06/2025 |
| gabapentin | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| quetiapine fumarate | Tablet, film coated | 28.784 mg | Resolved | Available | Unexpected increase in consumer demand | 13/06/2025 |
| celecoxib | Capsule, hard | 200 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| methotrexate | Injection, solution | 100 mg/mL | Current | Unavailable | Manufacturing | 13/06/2025 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Manufacturing | 13/06/2025 |
| irbesartan | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 13/06/2025 |
| emtricitabine~efavirenz~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~600 mg~300 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| ivabradine hydrochloride | Tablet, film coated | 5.39 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~20 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 25 mg~40 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| mercaptopurine monohydrate | Tablet | 50 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| potassium chloride | Injection, concentrated | 75 mg/mL | Resolved | Available | Commercial Changes / Commercial viability | 13/06/2025 |
| lurasidone hydrochloride | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| lacosamide | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| levothyroxine sodium | Tablet, uncoated | 100 microgram | Current | Unavailable | Manufacturing | 13/06/2025 |
| levothyroxine sodium | Tablet, uncoated | 50 microgram | Current | Unavailable | Manufacturing | 13/06/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| paracetamol | Tablet, modified release | 665 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 13/06/2025 |
| oxazepam | Tablet, uncoated | 30 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Unexpected increase in consumer demand | 13/06/2025 |
| levothyroxine sodium | Tablet | 75 microgram | Current | Unavailable | Manufacturing | 13/06/2025 |
| melatonin | Capsule, hard | 2 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/06/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Limited Availability | Manufacturing | 13/06/2025 |
| rifampicin | Capsule, hard | 300 mg | Anticipated | Available | Manufacturing | 13/06/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Resolved | Available | Manufacturing | 13/06/2025 |
| cefalexin monohydrate | Capsule, hard | 275 mg | Anticipated | Available | Manufacturing | 13/06/2025 |
| albendazole | Tablet, chewable | 400 mg | Current | Unavailable | Manufacturing | 13/06/2025 |
| atazanavir sulfate | Capsule, hard | 227.79 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/06/2025 |
| verapamil hydrochloride | Tablet, modified release | 240 mg | Current | Limited Availability | Manufacturing | 12/06/2025 |
| live varicella vaccine | Injection, powder for | 2700 PFU/mL | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 12/06/2025 |
| dienogest~ethinylestradiol | Tablet, sugar coated | 2 mg~.03 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| olanzapine | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 12/06/2025 |
| gabapentin | Tablet, film coated | 800 mg | Current | Unavailable | Manufacturing | 12/06/2025 |
| tramadol hydrochloride~paracetamol | Tablet, film coated | 37.5 mg~325 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| phenoxymethylpenicillin potassium | Tablet, film coated | 560 mg | Anticipated | Available | Manufacturing | 12/06/2025 |
| midazolam | Injection, solution | 5 mg | Current | Unavailable | Manufacturing | 12/06/2025 |
| leuprorelin acetate~bicalutamide | Injection, modified release~Tablet, film coated | 22.5 mg~50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| leuprorelin acetate~bicalutamide | Injection, modified release~Tablet, film coated | 7.5 mg~50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| bicalutamide~leuprorelin acetate | Injection, modified release~Tablet, film coated | 50 mg~22.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| metoclopramide hydrochloride monohydrate | Injection, solution | 10.54 mg | Resolved | Available | Unexpected increase in consumer demand | 12/06/2025 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, solution | 40 mg/mL~260 mg/mL | Current | Unavailable | Manufacturing | 12/06/2025 |
| cytarabine | Injection, solution | 100 mg/mL | Current | Limited Availability | Manufacturing | 12/06/2025 |
| cyproterone acetate~ethinylestradiol | Tablet, sugar coated | 2 mg~35 microgram | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| moxifloxacin | Injection, intravenous infusion | 1.6 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| cefalexin | Oral Liquid, powder for | 25 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 12/06/2025 |
| tramadol hydrochloride | Capsule | 50 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| salbutamol sulfate | Inhalation, conventional | 6 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 11/06/2025 |
| dexamethasone~gramicidin~framycetin sulfate | Ear Drops | .5 mg/mL~.05 mg/mL~5 mg/mL | Current | Unavailable | Manufacturing | 11/06/2025 |
| prilocaine~lidocaine | Gel | 42.5 mg~42.5 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 11/06/2025 |
| olanzapine | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Resolved | Available | Manufacturing | 11/06/2025 |
| pioglitazone hydrochloride | Tablet, uncoated | 33.06 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| aripiprazole | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in consumer demand | 11/06/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| candesartan cilexetil | Tablet, uncoated | 16 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| atorvastatin calcium trihydrate~amlodipine besilate | Tablet, film coated | 43.376 mg~6.94 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| escitalopram oxalate | Tablet, film coated | 25.548 mg | Resolved | Available | Manufacturing | 11/06/2025 |
| oxycodone hydrochloride | Capsule, hard | 20 mg | Resolved | Available | Commercial Changes / Commercial viability | 11/06/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| Pegfilgrastim | Injection, solution | 6 mg | Resolved | Available | Manufacturing | 11/06/2025 |
| dimethyl fumarate | Capsule, enteric | 120 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 11/06/2025 |
| dorzolamide hydrochloride~timolol maleate | Eye Drops, solution | 22.26 mg/mL~6.83 mg/mL | Current | Limited Availability | Manufacturing | 11/06/2025 |
| daptomycin | Injection, powder for | 500 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| framycetin sulfate~dexamethasone~gramicidin | Ear Drops | 5 mg/mL~.5 mg/mL~.05 mg/mL | Current | Limited Availability | Manufacturing | 11/06/2025 |
| lidocaine hydrochloride | Injection, solution | 20 mg/mL | Current | Unavailable | Manufacturing | 11/06/2025 |
| timolol maleate | Eye Drops, solution | 6.84 mg/mL | Resolved | Available | Commercial Changes / Commercial viability | 11/06/2025 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 11/06/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Anticipated | Available | Manufacturing | 11/06/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Limited Availability | Manufacturing | 11/06/2025 |
| lorazepam | Tablet, uncoated | 1 mg | Current | Unavailable | Manufacturing | 10/06/2025 |
| midazolam | Injection, solution | 1 mg/mL | Resolved | Available | Manufacturing | 10/06/2025 |
| honey bee venom | Injection, powder for | 550 microgram | Current | Unavailable | Manufacturing | 10/06/2025 |
| hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| perindopril erbumine~indapamide hemihydrate | Tablet | 4 mg~1.25 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 10/06/2025 |
| atorvastatin calcium trihydrate~amlodipine besilate | Tablet, film coated | 10.844 mg~13.88 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| bendamustine hydrochloride | Injection, powder for | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/06/2025 |
| bendamustine hydrochloride | Injection, powder for | 25 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/06/2025 |
| oxycodone hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Commercial Changes / Commercial viability | 10/06/2025 |
| epirubicin hydrochloride | Injection, concentrated | 200 mg | Resolved | Available | Manufacturing | 10/06/2025 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Resolved | Available | Manufacturing | 10/06/2025 |
| amiodarone hydrochloride | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 10/06/2025 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Current | Limited Availability | Manufacturing | 10/06/2025 |
| hydralazine hydrochloride | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 10/06/2025 |
| ethosuximide | Capsule, soft | 250 mg | Current | Unavailable | Manufacturing | 10/06/2025 |
| sodium chloride | Injection, intravenous infusion | 900 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/06/2025 |
2025年6月15日